Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells

Cancer Letters

Volumn 105, Issue 1, 1996, Pages 5-14

  El Akawi, Z ^a   Abu Hadid, M ^a   Perez, R ^a   Glavy, J ^a   Zdanowicz, J ^a   Creaven, P J ^a   Pendyala, L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Glutathione; Oxaliplatin; Resistance; glutamyl cysteine synthetase; glutamyl transpeptidase

Indexed keywords

BETA ACTIN; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; MESSENGER RNA; OXALIPLATIN;

ARTICLE; CARCINOMA CELL; COLORIMETRY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GLUTATHIONE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030593463     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04245-0     Document Type: Article

References (33)

1. [1] Abu-hadid, M.M., Fuji, H., Hsu, S. and Sood, A. (1996) A one step PCR procedure for analysis of tumor specific T lymphocyte responses. J. Immunol. Methods, 190, 91-105.
2. [2] Anderson, M.E. and Meister, A. (1983) Transport and direct utilization of gamma glutamylcyst(e)ine for glutathione synthesis. Proc. Natl. Acad. Sci. USA., 80, 707-711.
3. [3] Bailey, H.H., Gipp, J.J., Ripple, M., Wilding, G. and Mulcahy, R.T. (1992) Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res., 52, 5115-5118.
4. [4] Behrens, B.C., Hamilton, T.C., Masuda, H., Grotzinger, K.R., Whang-Peng, J. et al. (1987) Characterization of a cisdiamminedichloroplatinum (II) resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47, 414-418.
5. [5] Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 52, 5115-5118.
6. [6] Christian, M. (1992) The current status of new platinum analogs. Semin. Oncol., 19, 720-733.
7. [7] Deleve, L.D. and Kaplowitz, N. (1991) Glutathione metabolism and its role in hepatotoxicity. Pharmacol. Ther., 52, 287-305.
8. [8] Extra, J.M., Espie, M., Calvo, F., Ferme, C., Mignot, L. and Marty, M. (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25, 299-303.
9. [9] Fahey, R.C. and Newton, G.L. (1985) Determination of low molecular weight thiols using monobromobimane fluorescent labelling and high performance liquid chromatography. Methods Enzymol., 113, 85-96.
10. [10] Gipp, J.J., Chang, C. and Mulcahy, T. (1992) Cloning and nucleotide sequence of a full-length cDNA for human liver gamma glutamylcysteine synthetase. Biochem. Biophys. Res. Commun., 185, 29-35.
11. [11] Godwin, A.K., Meister, A., O'Dwyer, P.J., Huang, C.S., Hamilton, T.C. and Anderson, M.E. (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA, 89, 3070-3074.
12. [12] Hochwald, S.N., Harrison, L.E., Rose, M., Anderson, M. and Burt, M.E. (1996) Gamma-glutamyl transpeptidase mediation of tumor glutathione utilization in vivo. J. Natl. Cancer Inst., 88, 193-197.
13. [13] Ishikawa, T. and Wright, C.D. (1995) GS-X pump and γ-glutamylcysteine synthetase are co-overexpressed in cisplatin-resistant human leukemia HL-60 cells. Proc. Am. Assoc. Cancer Res., 36, 313.
14. [14] Lewis, A.D., Hayes, J.D. and Wolf, C.R. (1988) Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis, 9, 1283-1287.
15. [15] Mathe, G., Kidani, Y., Segiguchi, M., Eriguchi, M., Fredj, G., Peytavin, G., Misset, J.L., Brienza, S., de Vassals, F., Chenu, E. and Bourut, C. (1991) Oxalato-platinum or oxaliplatin, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43, 237-250.
16. [16] Meister, A. (1988) Novel Drugs that affect glutathione metabolism. In: Mechanisms of Drug Resistance in Neoplastic Cells, pp. 99-126. Editors: P.V. Woolley, III and K.D. Tew. Academic Press, New York.
17. [17] Meister, A. (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther., 51, 155-194.
18. [18] Misset, J.L., Kidani, Y., Gastiaburu, J., Jasmin, C., Levi, F., Boughattas, N., Lemaigre, G., Caussanel, J.P., Brienza, S., Kim Triana, B., Goldschmidt, M., Musset, M., Mauvernay, R.Y. and Mathe, G. (1991) Oxalatoplatinum (1-OHP): experimental and clinical studies. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 369-375. Editor: S.B. Howell. Plenum Press, New York.
19. [19] Moscow, J.A. and Dixon, K.H. (1993) Glutathione-related enzymes, glutathione and multidrug resistance. Cytotechnology, 12, 155-170.
20. [20] Mulcahy, R.T., Bailey, H.H. and Gipp, J.J. (1994) Upregulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother. Pharmacol., 34, 67-71.
21. [21] Mulcahy, R.T., Untawale, S. and Gipp, J. (1994) Transcriptional up-regulation of gamma glutamyl cysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells. Mol. Pharmacol., 46, 909-914.
22. [22] Naftalin, L., Sexton, M., Whitaker, J.F. and Tracey, D. (1969) A routine procedure for estimating serum gamma-glutamyl transpeptidase activity and its clinical applications. Clin. Chim. Acta, 26, 293-296.
23. [23] Nardi, G. and Cipollaro, M. (1990) Assay of gamma-glutamylcysteine synthetase and glutathione synthetase in erythrocytes by high performance liquid chromatography with fluorimetric detection. J. Chromatogr., 530, 122-128.
24. [24] Perez, R.P., Hamilton, T.C. and Ozols, R.F. (1990) Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol. Ther., 48, 19-27.
25. [25] Ponte, P., Ng, S.Y., Engel, J., Gunning, P. and Kedes, L. (1984) Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res., 12, 1687-1696.
26. [26] Pratesi, G., Dal Bo, L., Paolicchi, A., Tonarelli, P., Tongiani, R. and Zunino, F. (1995) The role of glutathione dependent system in tumor sensitivity to cisplatin: a study of human tumor xenografts. Ann. Oncol., 6, 283-289.
27. [27] Rajpert-De Meyts, E., Heisterkamp, N. and Groffen, J. (1988) Cloning and nucleotide sequence of human gamma glutamyl transpeptidase. Proc. Natl. Acad. Sci. USA, 85, 8840-8844.
28. [28] Richon, V.M., Schulte, N. and Eastman, A. (1987) Multiple mechanisms of cellular resistance to platinum coordination complexes. Cancer Res., 47, 2056-2061.
29. [29] Rubinstein, L.V., Shoemaker, R.H., Paull, K.D., Simon, R.M., Tosini, S. et al. (1990) Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 82, 1113-1118.
30. [30] Warren, W. and Doniger, J. (1991) HPLC purification of polymerase chain reaction products for direct sequencing. BioTechniques, 10, 216-219.
31. [31] Warren, W., Wheat, T. and Knudsen, P. (1991) Rapid analysis and quantitation of PCR products by high performance liquid chromatography. BioTechniques, 11, 250-255.
32. [32] Yao, K., Godwin, A., Ozols, R.F., Hamilton, T.C. and O'Dwyer, P.J. (1993) Variable baseline gamma glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res., 53, 3662-3666.
33. [33] Yao, K., Godwin, A.K., Johnson, S.W., Ozols, R.F., O'Dwyer, P.J. and Hamilton, T.C. (1995) Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin sensitive and cisplatin resistant human ovarian carcinoma cell lines. Cancer Res., 55, 4367-4374.